Molecular pathways supporting the proliferation staging of malignant melanoma (review)
- PMID: 19639220
- DOI: 10.3892/ijmm_00000232
Molecular pathways supporting the proliferation staging of malignant melanoma (review)
Abstract
The clinical diagnosis of cutaneous melanoma always calls for histological confirmation. In addition to the recognition of the classic aspects of the neoplasm, immunohistochemistry is determinant, in particular in the assessment of the size of the replicative compartment. Generally, the proliferation rate is indicative of the neoplastic progression and is related to the clinical growth rate of the neoplasm. It allows to distinguish high risk melanomas showing a high growth rate from those of lower malignancy associated with a restricted growth rate. In melanoma, the recruitment and progression of neoplastic cells in the cell cycle of proliferation have lost some of their controls that are normally processed by a series of key regulatory molecules. In addition, the apoptotic pathway counteracting any hyperproliferative activity is released of the dependency of specific regulated molecular mechanisms. This review summarizes the current knowledge on key molecular components involved in the deregulation of the growth fraction, cell proliferation and apoptosis in melanocytic neoplasms. The implication of cyclins and of the mitogen-activated protein kinase pathways are scrutinized. The involvement of neoplastic stem cells in the metastatic process is also discussed.
Similar articles
-
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.ISRN Dermatol. 2012;2012:828146. doi: 10.5402/2012/828146. Epub 2012 Jan 11. ISRN Dermatol. 2012. PMID: 22363864 Free PMC article.
-
Expression of cyclins and cyclin dependent kinases in human benign and malignant melanocytic lesions.J Clin Pathol. 2001 Mar;54(3):229-35. doi: 10.1136/jcp.54.3.229. J Clin Pathol. 2001. PMID: 11253137 Free PMC article.
-
Immunohistochemical analysis of the S100A1, S100B, CD44 and Bcl-2 antigens and the rate of cell proliferation assessed by Ki-67 antibody in benign and malignant melanocytic tumours.Melanoma Res. 2010 Apr;20(2):118-25. doi: 10.1097/CMR.0b013e3283350554. Melanoma Res. 2010. PMID: 20042890
-
[Role of cancer stem cells in the progression and heterogeneity of melanoma].Orv Hetil. 2016 Aug;157(34):1339-48. doi: 10.1556/650.2016.30487. Orv Hetil. 2016. PMID: 27546799 Review. Hungarian.
-
Growth and progression of melanoma and non-melanoma skin cancers regulated by ubiquitination.Pigment Cell Melanoma Res. 2010 Jun;23(3):338-51. doi: 10.1111/j.1755-148X.2010.00692.x. Epub 2010 Mar 8. Pigment Cell Melanoma Res. 2010. PMID: 20230483 Review.
Cited by
-
Dextran-catechin conjugate: a potential treatment against the pancreatic ductal adenocarcinoma.Pharm Res. 2012 Sep;29(9):2601-14. doi: 10.1007/s11095-012-0790-9. Epub 2012 May 24. Pharm Res. 2012. PMID: 22622510
-
Ipilimumab, a promising immunotherapy with increased overall survival in metastatic melanoma?Dermatol Res Pract. 2012;2012:182157. doi: 10.1155/2012/182157. Epub 2011 Oct 23. Dermatol Res Pract. 2012. PMID: 22046181 Free PMC article.
-
Smouldering malignant melanoma and metastatic dormancy: an update and review.Dermatol Res Pract. 2012;2012:461278. doi: 10.1155/2012/461278. Epub 2011 Nov 2. Dermatol Res Pract. 2012. PMID: 22110487 Free PMC article.
-
Cell proliferation in cutaneous malignant melanoma: relationship with neoplastic progression.ISRN Dermatol. 2012;2012:828146. doi: 10.5402/2012/828146. Epub 2012 Jan 11. ISRN Dermatol. 2012. PMID: 22363864 Free PMC article.
-
Molecular dermatopathology in malignant melanoma.Dermatol Res Pract. 2012;2012:684032. doi: 10.1155/2012/684032. Epub 2011 Oct 20. Dermatol Res Pract. 2012. PMID: 22028703 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical